ceo step stori remain transit evolv landscap reiter
first take earn
novarti earn read-through coverag
verizon give disney boost
novn sma pnh readthrough
public contain summari recent credit suiss research report bring notabl research attent full report summari
certif legal entiti disclosur inform statu non-u analyst equiti research disclosur click
price month
expect volatil even report revenu ep organ
cse/st /guid
result help acceler us market revenu organ
financi servic organ emerg vertic strong
intern perform organ growth rel cs uk india
canada report double-digit organ growth said emerg vertic
us total revenu revenu deceler organ stack
like stori applaud solid result coupl conserv
guid need see balanc risk/reward stock lever yield
amid firmer macro revisit thesi continu
recommend investor seek exposur credit bureau ecosystem strateg
boost ep introduc
prior roll forward valuat higher multipl
guid call ep rel cse/st also impli modest deceler
growth expect organ rel believ guidanc could
conserv given beaten consensu consist past sever quarter amid
rel healthi macro
positivesorgan growth acceler driven divers products/geographi ebitda margin
expans well expect yoy rel cse expect
addit well expect cse though partial driven
lower capital-expenditure work capit benefit
negativesrevenu ebitda guid modestli estim amid ep larg line
like due lower interest burden debt repay addit emerg vertic
deceler stack
tp prior equat ev/ebitda compar rang
averag risksmacro uncertainti intern us consum credit/
mortgag soft underwhelm new product uptick
date product utc date dissemin utc
share under-perform sinc ceo alan schnitzer first pre-
announc higher loss-infl trend confer point short interest
increas approx go today print wed expect cover rotat
name given extent move today ntm consensu price-to-earnings versu
like lesser declin forward consensu estim especi given trv new
fundament analyst versu passiv like still see rel safeti
manag elicit confid price inde in-lin ahead loss inflat
trend though management clear price still bias higher posit read-though
insur broker point decad sinc liabil loss-infl
level reach current mid-singl digit level intern actuari continu grappl
whether today materi higher trend-lin continu rise management mention would
becom activ lobbi state/feder tort reform recent report highlight rise
litig financ institut asset class neg impact insur industri
like garner eventu reform plaintiff least disclos insur whether
parti capit also advertis back lawsuit would like caus insur
increas estim sever case make higher cost less surpris
see posit insur broker due price momentum
better expect worker comp loss-infl trend posit hartford
overweight line great person auto result appear take
view frequenc stay low/neg longer posit though keep
mind miss good amount homeown make allstat
date product utc date dissemin utc
price month
price month
off-set catastroph ep versu cs visibl alpha
consensu recal alreadi factor defici reserv main bi
comml segment given industrywid trend trv asbesto review ceo schnitzer
comment recent confer see note share under-perform
conf call
management pre-account price show momentum busi price
vs expect management express feel price excess
loss-trend call
loss ratio margin vs y/i wors estimate driven
segment person auto commerci auto gener liabil home main
underli miss culprit worker comp continu trend better expect management
improv pick point expens ratio vs y/i
came better estimate trend like driven better expect
top-lin growth past year guidanc call core margin improv within
commerci segment homeown first though core loss ratio
within bond sureti segment expect remain elev near term due higher loss-
reserv defici compar slightli posit reserv releas y/i
reserv addit relat legaci asbesto environment claim shouldnt
surpris remain came larg commerci auto gener liabil ceo
alan schnitzer allud recent confer
net invest incom hurt lower yield guidanc call flattish y/i level
quarterli first compar previou
guidanc million y/i flattish given declin interest rate
point shouldnt surpris investor given big drop yield howev
notabl current consensu estim emb slightli higher net invest incom level
date product utc date dissemin utc
ceo step stori remain transit
evolv landscap reiter neutral
ceo transitionlog step benjamin shaw step compani
presid ceo effect immedi albeit remain strateg advisor board
conjunct benjamin wolin current chairman assum role act ceo
presid note appoint chairman earli septemb follow departur
david shaw board view transit logic clear misstep sinc
februari spin guidanc reduct view deplet market share
convent distributor new e-commerc competitor follow month share
volatil recent company-specif weak across broader suppli chain busi david
shaw departur board view top manag transit ration albeit
potenti earlier expect remind recent lower ebitda estim
target price last week like continu challeng evolv competit landscap
reiter neutral cvet share fallen to-dat vs two
consecut guidanc cut predic custom loss distribut disrupt increment
cost recur expens relat exit tsa view potenti upsid share
limit target price predic ev/ebitda multipl discount
forward ebitda competitor mwi acquir broader
anim health peer group view warrant given aforement challeng
risk includ share shift breach debt coven traction synergi captur
date product utc date dissemin utc
third quarter earn valid strong oper result
mi industri walk key takeaway earn call
capit return quarter repurchas million share estim
million share combin cash million hold compani
dividend hold compani least million annual less million debt servic
million dividend remain posit repurchas share manag continu
expect opportunist share repurchas result slower pace activ
fourth quarter share current higher averag repurchas price
higher level
market share gain niw higher expect quarter
first mi report earli know much upsid market share gain vs
larger market manag say think regain market share quarter
lost bp first half manag priorit market share
recogn import maintain relev market
price premium rate niw declin bp quarter
year-to-d manag indic much declin relat mix shift
higher qualiti loan less ltv less dti target return capit
niw unchang prior quarter rate card longer primari price
mechan industri look price differenti rate card support
manag commentari qualiti shift niw explain premium rate move
exampl dti loan carri bp higher rate ltv carri bp
higher rate declin high dti high ltv polici quarter account
premium rate declin
date product utc date dissemin utc
price month
price month
first take earn
ep miss global momentum continu ep sell-sid
consensu larg driven lower expect revenu higher expect
 higher expect tax us compstore slight miss sell-
side though like in-lin buy-sid expect driven nation local deal
offer promot posit contribut experi futur eotf menu
price increas intern oper market iom compstore reflect posit result
across market primarili driven uk franc consensu
development licens market compstore acceler consensu strong
perform across region
chang outlook sg expect increas ex-fx rel flat
driven invest technolog relat recent acquisit dynam yield
apprent interest expens expect increas tax rate
expect
us breakfast busi perform improv drive-through
servic time primari driver compstore signific us
out-performance quarter composit compstore traffic/ticket
meaning driver compstore deliveri contribut
quarter updat regard roll-out doordash earli feedback
perform test store canada plan expand test canada us
compstore contribut digit menu board much system
implement digit menu board dynam yield technolog impact
lab capital-expenditure run rate go forward dynam yield still
oper separ busi sole focus
store current test apprent voic technolog thought potenti time roll-out
date product utc date dissemin utc
novarti earn read-through
novarti report earn earlier morn provid sever read-through
coverag includ regeneron eylea dupix biogen spinraza ms
pipelin gilead yescarta collabor work incyt jakavi
regeneron eylea call manag reiter confid beovu abil disrupt
wamd space earlier month fda approv beovu wamd dose option
compar per vial price recal beovu anti-vegf wet
recommend maintain elig patient three-month dose interv immedi
load phase expect novarti offer aggress contract rebat attract invoic
term econom incent doctor use beovu anticip beovu take share
therapi wamd includ eylea roch lucenti beovu continu roll-out
crowd anti-vegf market forecast continu eylea eros sale peak
long-term think competit biosimilar may take consider share lucenti
eylea term diabet retinopathi dr expect minim effect novarti
lucenti per novartis/roch collabor novarti respons ex-u sale
regeneron sole respons us eylea sale share ex-u profit bayer note
core neutral thesi regeneron expect competit dr minim impact
overal ophthalmolog franchis
 spinraza novarti report us sale recent launch zolgensma
type spinal muscular atrophi sma patient rang year-old recal
june novarti self-disclos fda health author eu japan data
previous submit bla packag inaccur manag commentari
call relat zolgensma line under-perform thesi continu believ
zolgensma neg impact spinraza sale trajectori view zolgensma differenti
spinraza term efficaci toler standpoint chronic spinal infus
difficult endur howev still expect roche/ptc risdiplam greater threat
sma space expect spinraza sale erod start note
discuss spinraza earn call morn given focu ad updat
concern remain durabl franchis
gilead yescarta novarti report sale kymriah refractori non-hodgkin
lymphoma kymriah anoth t-cell therapi serv direct competitor gilead yescarta
forecast sale kymriah growth mainli driven on-going uptak
us europ qualifi treatment center countri world-wide
coverag least one indic expect gilead cell therapi franchis drive top-
line growth near term expect minim impact kymriah yescarta sale
date product utc date dissemin utc
verizon give disney boost
disney verizon announc market partnership wherebi verizon give free year
disney exist new unlimit wireless custom new broadband internet
custom fio smart deal view compani wireless
market partnership exclus verizon continu least june deadlin
sign verizon websit though promot could extend deem success
custom free year disney end verizon websit indic expect
start charg custom normal retail price though manag indic
earli gaug whether extend free/discount period deal opt-in
structur verizon custom activ subscript verizon websit
count disney custom deal surprisingli verizon wholesal rate
improv volum increas
disney obvious big boost market disney servic start
verizon offer free current unlimit wireless consum household
new unlimit wireless internet household verizon attract next half year
cse respect though overlap new broadband
custom unlimit verizon home perhap hh total deal
verizon pay custom activ disney account receiv volum
discount wholesal price imagin vs previou deal disney offer consum
alreadi rang year commit vs retail
price view addit market boost start smart bundl custom
first year get point origin start ramp adult first marvel
tv seri launch next fall well verizon convert unlimit wireless
custom disney account whether disney convert free verizon account pay
disney account free month period interest see verizon
extend exclus arrang disney next summer whether wireless
compani step market support though alreadi partner sprint
hulu bundl hbo max
verizon signific market spend next month perhap around
hh opt-in wholesal rate month vs
wireless revenu time expect verizon aggress use disney
market smartli align premium brand particip launch growth
new premium servic vs discount alreadi exist servic use disney
tri drive unlimit penetr higher follow august price shift
increment disney invest among initi seem clear point verizon
focus maxim posit go tri drive market share end
cycl reduc churn move mani peopl unlimit possibl
eas tri upsel move custom unlimit avail scale
date product utc date dissemin utc
novn sma pnh readthrough
sma readthrough multipl sma updat novarti earn
outlin base strong growth sma market remain confid
estim ptc/roch risdiplam achiev sale peak expect risdiplam
approv see strateg posit strong uptak type
sma popul oral administr vs spinraza everi month intrathec
inject potenti differenti efficaci could larg supplant spinraza current market
leadership expect zolgensma captur vast major incid type
sma popul anticip risdiplam emerg domin therapi older sma
patient interact model detail
novarti updat compani report zolgensma sale first full
quarter drug market compani guid larg flat sale
rel reflect treatment pent-up demand specif detail
respect us launch includ
reimburs commerci patient medicaid patient cover
insur plan cover zolgensma said plan allow patient take one drug
 wont reimburs zolgensma spinraza final approv rate
number center prescrib drug treat institut across us
percentag patient switch spinraza
look ahead novarti see potenti growth driven increas us newborn screen
newborn today ye new medicaid polici florida new
jersey michigan addit compani expect zolgensma chmp eu jpn decis
delay due time manufactur plant re-inspect
respect compani submit strong sma type low mid-dos data
fda await feedback intrathec file approach treatment older preval
sma patient compani continu guid regulatori file
updat report spinraza revenu vs consensu
factset patient drug across post-market set expand
access program eap clinic trial end bulk
growth uptak drug exu treat patient exu vs treat patient
us us number adult spinraza patient grew vs
date product utc date dissemin utc
